InflaRx
InflaRx
IFRX
NASDAQ
1.17
USD
-4.88%
About
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases.
The Company's product pipeline also includes IFX-2, which is in preclinical development..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 72.2K |
| Three Month Average Volume | 1.7M |
| High Low | |
| Fifty-Two Week High | 4.3 USD |
| Fifty-Two Week Low | 1.14 USD |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 10 Nov 2023 |
| Price and Volume | |
| Current Price | 1.59 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 2.38% |
| Thirteen Week Relative Price Change | 3.89% |
| Twenty-Six Week Relative Price Change | -17.37% |
| Fifty-Two Week Relative Price Change | -67.88% |
| Year-to-Date Relative Price Change | -17.63% |
| Price Change | |
| One Day Price Change | -4.22% |
| Thirteen Week Price Change | 11.19% |
| Twenty-Six Week Price Change | -9.14% |
| Five Day Price Change | 0.63% |
| Fifty-Two Week Price Change | -59.75% |
| Year-to-Date Price Change | -2.45% |
| Month-to-Date Price Change | 6.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.9287 USD |
| Book Value Per Share (Most Recent Quarter) | 1.54465 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.92741 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.54381 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.97368 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00127 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00198 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.8598 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.8811 USD |
| Normalized (Last Fiscal Year) | -0.8598 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.8598 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.8811 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.8598 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.8811 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.69727 USD |
| Cash Per Share (Most Recent Quarter) | 1.40995 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.84835 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.8711 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.81223 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -304,636 |
| Cash Flow Revenue (Trailing Twelve Months) | -40,966 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -44,444.54% |
| Pretax Margin (Last Fiscal Year) | -67,629.63% |
| Pretax Margin (5 Year) | -324,965.30% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -743.65% |
| Gross Margin (Trailing Twelve Months) | -943.64% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -71,181.01% |
| Operating Margin (Trailing Twelve Months) | -49,618.39% |
| Operating Margin (5 Year) | -341,562.50% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -67,629.63% |
| Net Profit Margin (Trailing Twelve Months) | -44,444.54% |
| Net Profit Margin (5 Year) | -324,965.30% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -21.46% |
| Tangible Book Value (5 Year) | -7.47% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -36.83% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -63.37% |
| EPS Change (Trailing Twelve Months) | -5.80% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -81,875,940 |
| Net Debt (Last Fiscal Year) | -98,659,890 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1.3K |
| Price to Sales (Trailing Twelve Months) | 803 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 1 |
| Long Term Debt to Equity (Most Recent Quarter) | 1 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 6 |
| Quick Ratio (Most Recent Quarter) | 8 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -41,952,560 |
| Free Cash Flow (Trailing Twelve Months) | -47,843,040 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 1 |
| Total Debt to Equity (Most Recent Quarter) | 1 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -38.33% |
| Return on Assets (Trailing Twelve Months) | -41.49% |
| Return on Assets (5 Year) | -35.53% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -44.69% |
| Return on Equity (Trailing Twelve Months) | -45.34% |
| Return on Equity (5 Year) | -40.55% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -44.28% |
| Return on Investment (Trailing Twelve Months) | -45.02% |
| Return on Investment (5 Year) | -40.29% |